Stockreport

Concert Pharmaceuticals Initiates Phase 1 Multiple-Ascending Dose Trial of CTP-692 as an Adjunctive Treatment for Schizophrenia

Concert Pharmaceuticals, Inc.  (CNCE) 
Last concert pharmaceuticals, inc. earnings: 4/30 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: ir.concertpharma.com/investor-relations
PDF LEXINGTON, Mass.--(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has initiated an additional trial in the Phas [Read more]